Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 582
- Registration Number
- NCT04880850
- Locations
- 🇺🇸
UT Southwestern Med Cntr, Dallas, Texas, United States
🇯🇵Noritake Clinic, Ushiku-shi, Ibaraki, Japan
🇺🇸Amarillo Med Spec LLP, Amarillo, Texas, United States
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men
- Conditions
- Healthy Volunteers Type 2 Diabetes
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT04878406
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Fukuoka, Japan
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 650
- Registration Number
- NCT04878393
- Locations
- 🇯🇵
Master Centre for Japan, Tokyo, Japan
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
- Conditions
- Chronic Kidney DiseaseDiabetes Mellitus, Type 2
- Interventions
- Drug: Placebo (Semaglutide)
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 106
- Registration Number
- NCT04865770
- Locations
- 🇿🇦
Prof Rayner_Division of Nephrology, Cape Town, Western Cape, South Africa
🇺🇸Academic Medical Research Institute, Los Angeles, California, United States
🇺🇸N America Res Inst - San Dimas, San Dimas, California, United States
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 336
- Registration Number
- NCT04862923
- Locations
- 🇬🇧
Master Centre for United Kingdom, Crawley, United Kingdom
A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 Diabetes
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT04857398
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 582
- Registration Number
- NCT04848480
- Locations
- 🇯🇵
Yuri Ono Clinic, Sapporo-shi, Hokkaido, Japan
🇬🇧Churchill Hospital, Oxford, United Kingdom
🇬🇧Lister Hospital, Stevenage, United Kingdom
GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 244
- Registration Number
- NCT04838743
- Locations
- 🇯🇵
Budounoki Clinic, Saga-shi, Saga, Japan
🇯🇵Seino Internal Medicine Clinic, Koriyama-shi, Fukushima, Japan, Japan
🇯🇵Kawada Clinic, Gunma, Japan
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1205
- Registration Number
- NCT04822181
- Locations
- 🇬🇧
The Diabetes Centre, Ipswich, United Kingdom
🇬🇧St. James University Hospital, Leeds, United Kingdom
🇷🇴SC Diamed Obesity SRL, Galati, Romania
A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 14
- Registration Number
- NCT04817644
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
🇺🇸ICON-Salt Lake City, Salt Lake City, Utah, United States